PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
88.49%
R&D growth while GNPX reduces spending. John Neff would investigate strategic advantage.
34.89%
G&A growth 50-75% of GNPX's 52.68%. Bruce Berkowitz would examine operational efficiency.
No Data
No Data available this quarter, please select a different quarter.
77.92%
Other expenses change of 77.92% while GNPX maintains costs. Bruce Berkowitz would investigate efficiency.
59.22%
Operating expenses growth above 1.5x GNPX's 17.95%. Michael Burry would check for inefficiency.
59.22%
Total costs growth above 1.5x GNPX's 17.95%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
77.92%
D&A growth while GNPX reduces D&A. John Neff would investigate differences.
-37.27%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-59.22%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-87.81%
Other expenses reduction while GNPX shows 46.73% growth. Joel Greenblatt would examine advantage.
-272.88%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-272.88%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-252.38%
EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
-313.33%
Diluted EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
10.47%
Share count reduction exceeding 1.5x GNPX's 80.76%. David Dodd would verify capital allocation.
-20.54%
Diluted share reduction while GNPX shows 80.76% change. Joel Greenblatt would examine strategy.